Get the Stockscreener App
0.5404
3.15%
-0.0176
Pre-market:
.54
-0.0004
-0.07%
Longeveron Inc stock is traded at $0.5404, with a volume of 524.59K.
It is down -3.15% in the last 24 hours and down -9.93% over the past month.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
See More
Previous Close:
$0.558
Open:
$0.56
24h Volume:
524.59K
Relative Volume:
1.16
Market Cap:
$11.53M
Revenue:
$1.89M
Net Income/Loss:
$-17.92M
P/E Ratio:
-0.0808
EPS:
-6.69
Net Cash Flow:
$-15.62M
1W Performance:
-1.80%
1M Performance:
-9.93%
6M Performance:
-54.97%
1Y Performance:
-67.25%
1-Day Range:
$0.5349
$0.5686
1-Week Range:
$0.5333
$0.625
52-Week Range:
$0.5333
$2.24
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.5404 | 11.90M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.36 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.73 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
852.04 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.76 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Longeveron (NASDAQ:LGVN) Stock Price Down 3.2% – What’s Next? - Defense World
Will Longeveron Inc. stock attract more institutional investors2025 Market WrapUp & Weekly High Conviction Trade Ideas - Улправда
Comparing Longeveron (NASDAQ:LGVN) & Senti Biosciences (NASDAQ:SNTI) - Defense World
What drives Longeveron Inc stock priceDouble Top/Bottom Patterns & Trusted Financial Advisors at No Cost - earlytimes.in
Is Longeveron Inc. stock a good choice for value investorsNew Guidance & Verified Stock Trade Ideas - Улправда
Can Longeveron Inc. stock attract ESG capital inflowsIPO Watch & Weekly Breakout Watchlists - DonanımHaber
Is Longeveron Inc. stock a top momentum play2025 Bull vs Bear & Safe Entry Momentum Tips - DonanımHaber
What risks investors should watch in Longeveron Inc. stockPortfolio Return Summary & Comprehensive Market Scan Reports - DonanımHaber
Why Longeveron Inc. stock remains on watchlists2025 Valuation Update & Technical Confirmation Trade Alerts - DonanımHaber
Is Longeveron Inc. stock a buy in volatile marketsEarnings Trend Report & Precise Swing Trade Alerts - ulpravda.ru
What technical signals suggest for Longeveron Inc. stockEarnings Summary Report & Fast Moving Stock Trade Plans - Улправда
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction - Investing.com Canada
Longeveron granted U.S. patent for method of treating female sexual dysfunction - marketscreener.com
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction By Investing.com - Investing.com South Africa
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy - The Manila Times
Block Trades: What risks investors should watch in Longeveron Inc stockRate Cut & Free High Return Stock Watch Alerts - moha.gov.vn
Longeveron Earnings Notes - Trefis
Longeveron granted Canadian patent covering laromestrocel administration - MSN
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Prepare Yourself for Liftoff: Longeveron Inc (LGVN) - Setenews
With Longeveron Stock Sliding, Have You Assessed The Risk? - Trefis
Update Recap: Can MCK stock sustain institutional flowsWatch List & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Longeveron executives to speak at CVCT Forum on cell therapy trials - Investing.com Nigeria
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - The Manila Times
Longeveron (NASDAQ: LGVN) CSO, CMO to Join CVCT Forum Panels on Cell Therapy Trials - Stock Titan
Can Longeveron Inc. stock continue upward trendWeekly Trend Recap & Fast Entry Momentum Alerts - Newser
Longeveron (LGVN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Longeveron receives Canadian patent for stem cell therapy By Investing.com - Investing.com Nigeria
Perhaps timely catching Longeveron Inc (LGVN) would be a good idea - Setenews
Longeveron receives Canadian patent for stem cell therapy - Investing.com
Longeveron granted Canadian patent for method of using stem cells to treat non-ischemic dilated cardiomyopathy - MarketScreener
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - The Manila Times
Longeveron (NASDAQ: LGVN) gets Canada patent on LOMECEL-B for frailty and NIDCM - Stock Titan
Longeveron’s stem cell therapy shows reduced neuroinflammation in AD trial By Investing.com - Investing.com South Africa
Longeveron to present MRI biomarker data in Alzheimer’s at CTAD 2025 - TipRanks
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - The Manila Times
Longeveron (NASDAQ: LGVN) sees MRI inflammation drop in 13 of 14 brain regions at week 39 - Stock Titan
Longeveron’s stem cell therapy shows reduced neuroinflammation in AD trial - Investing.com
Longeveron (NASDAQ:LGVN) Shares Up 3% – Should You Buy? - Defense World
Longeveron announces board member resignation - MSN
Longeveron Inc. (LGVN) Jumps 6% in Pre-market: What’s Driving the Move? - Stocks Telegraph
Longeveron granted U.S. patent for administration of MSCs - MSN
Longeveron Inc. (LGVN) 5.03% in After-hours: What’s Driving the Move? - Stocks Telegraph
Take off with Longeveron Inc (LGVN): Get ready for trading - Setenews
What data driven models say about Longeveron Inc.’s futureJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Longeveron Inc. (LGVN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Longeveron to present Alzheimer's treatment data at CTAD 2025 By Investing.com - Investing.com Nigeria
Longeveron to present Alzheimer’s treatment data at CTAD 2025 By Investing.com - Investing.com Australia
Will Longeveron Inc. stock remain a Wall Street favorite2025 Dividend Review & Community Shared Stock Ideas - newser.com
Longeveron to present Alzheimer’s treatment data at CTAD 2025 - Investing.com
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - The Manila Times
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Longeveron Inc Stock (LGVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
0.67%
1.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):